From blocking to deleting
Every drug so far in this track has been an *occupancy* drug: it sits on the target and blocks it, but only while the molecule is physically present. The moment the drug washes away, the protein is free again. A targeted protein degrader flips the whole logic. It does not ask how do I block this protein? but the bolder question — how do I delete it?
Every cell already has a disposal service. Proteins that are old, broken, or unwanted get tagged with a small marker called ubiquitin, which flags them for the proteasome — the cell's shredder — to be chewed up and recycled. Degraders are molecules that trick this system into tagging a healthy cancer-driving protein as garbage. Instead of jamming the protein, the drug gets it thrown away.
PROTACs: a molecular matchmaker
A PROTAC is the cleverest expression of this idea. Picture a dumbbell: one end is a binder that grabs the target protein, the other end grabs one of the cell's ubiquitin-tagging machines, and a flexible linker joins them. The PROTAC itself does nothing to the target's function. Its whole job is to act as a matchmaker, dragging the disposal machinery and the doomed protein into the same embrace so the tag gets applied.
How a PROTAC works
===================
[ target binder ]──linker──[ E3 ligase binder ]
│ │
▼ ▼
cancer protein ←brought together→ ubiquitin-tagging machine
│
▼
ubiquitin tags slapped onto the protein
│
▼
proteasome (shredder) destroys it
│
▼
PROTAC falls off, intact, and goes to find the NEXT copyTwo properties make this remarkable. First, it is catalytic: after the target is shredded, the PROTAC drops off undamaged and goes to find the next copy. One molecule can destroy many targets, so it works at tiny doses. Second, it can drug the *undruggable*. Many cancer drivers — scaffolding proteins, transcription factors — have no deep pocket to block and were long judged poor in druggability. A degrader needs only enough of a foothold to *grab* the protein, not a functional site to obstruct, opening targets that defeated every classical inhibitor.
Molecular glues, and an honest verdict
A molecular glue reaches the same destination by a sleeker route. Rather than a bulky two-headed dumbbell, it is a small, ordinary-looking molecule that nestles at the *interface* between the target and the disposal machine, gluing two proteins that would normally ignore each other into a new protein–protein interaction. The cell then tags and shreds the trapped target. Thalidomide — once a notorious tragedy — turned out to be a molecular glue degrader, and its safer relatives now treat blood cancers.
Stand back and the arc of this track is one long climb in precision. We began with cytotoxic poisons that could only tell cells apart by how fast they divide; we pass through kinase inhibitors that block one named enzyme, covalent drugs that bond it shut, and ADCs that deliver poison by postcode; and we arrive at degraders that erase the offending protein from the cell entirely. None of these is a cure-all, and resistance still stalks every one of them. But each step has bought a little more of the one thing cancer chemistry has always lacked — the power to harm the tumour and spare the patient.